Leadless Pacemaker Implantation in Patients With Tricuspid Valve Disease

Tricuspid valve disease creates a distinctive pacing problem. Conventional transvenous pacemakers require a lead to pass through the tricuspid valve and remain in the right heart, which can worsen tricuspid regurgitation, interfere with prosthetic valve function, or complicate future valve surgery. Leadless pacemakers avoid a permanent transvalvular lead by placing the pacing device directly inside the right ventricle.

This approach has become clinically relevant for patients with severe tricuspid regurgitation, prior tricuspid valve repair, bioprosthetic valve replacement, or a high risk of infection. It is also being considered when venous access is limited or when a patient’s anatomy makes a conventional system unsuitable. The decision, however, requires more than identifying a damaged valve: pacing indications, ventricular function, rhythm history, device capability, and procedural risk must be assessed together.

For clinicians in Australia, patient selection also sits within a health system shaped by tertiary referral pathways, Therapeutic Goods Administration (TGA) requirements, Medicare-funded care, and unequal access to advanced electrophysiology services. Evidence from contemporary electrophysiology practice and arrhythmia research journal publications can support shared decisions, multidisciplinary review, and careful follow-up.

Why Tricuspid Valve Disease Changes Pacing Strategy

A transvenous right ventricular lead may contribute to tricuspid regurgitation through leaflet impingement, perforation, entanglement, or distortion of the subvalvular apparatus. The risk may be especially important when regurgitation is already moderate or severe. Progressive right-sided volume overload can lead to peripheral oedema, hepatic congestion, ascites, reduced exercise tolerance, and repeated hospital admissions.

The clinical relationship is bidirectional. Functional tricuspid regurgitation may enlarge the right atrium and ventricle, while a lead can aggravate coaptation failure. In a patient being considered for transcatheter or surgical tricuspid intervention, a lead crossing the valve may become an additional technical obstacle. Avoiding a transvalvular lead can therefore preserve future treatment options.

Leadless pacing is most relevant when the required therapy is ventricular demand pacing. It is less straightforward when the patient needs reliable atrioventricular synchrony, cardiac resynchronisation, defibrillation, or atrial pacing. The pacing indication should remain the starting point rather than allowing the valve lesion alone to dictate device choice.

Selecting Suitable Patients

Common candidates include adults with symptomatic bradycardia, atrioventricular block, or pauses who have significant tricuspid regurgitation and no immediate requirement for atrial or biventricular pacing. Patients with a tricuspid bioprosthesis may also benefit because a lead crossing the prosthesis can damage the valve or restrict leaflet motion. Prior infection of a transvenous system, an absent upper-limb venous route, and limited venous access are additional factors that may favour a leadless system.

Assessment should include transthoracic echocardiography, and often transoesophageal or three-dimensional imaging when valve anatomy is complex. The team should document regurgitation severity, right ventricular size and function, pulmonary pressures, prosthetic valve type, and the position of any prior annuloplasty ring. Electrocardiographic monitoring helps establish whether the patient has intermittent or persistent pacing dependence.

Leadless devices are not suitable for every patient. Severe right ventricular dysfunction, intracardiac thrombus, mechanical tricuspid valve replacement, active infection, unsuitable femoral venous anatomy, or a need for therapies beyond the device’s capabilities may alter the balance. A frail patient with a limited life expectancy may place greater value on procedural simplicity, while a younger patient requires careful discussion of retrieval, battery longevity, and future device accumulation.

Understanding Available Leadless Systems

Leadless pacemakers are delivered through a large femoral venous sheath and secured within the right ventricular endocardium, commonly in the septal or apical region. Earlier systems largely provided single-chamber ventricular pacing. Newer platforms may offer atrioventricular synchrony through mechanical sensing of atrial contraction or communication between implanted devices, although performance can vary with atrial rhythm, ventricular function, and activity.

The absence of a chest pocket removes pocket haematoma, pocket infection, and lead fracture as concerns. It also eliminates a lead crossing the tricuspid valve. The device still carries important risks, including cardiac perforation, pericardial effusion, vascular injury, dislodgement, thromboembolism, and difficulty retrieving or replacing a depleted unit.

Device selection should reflect the expected pacing burden and the patient’s anatomy. A patient likely to require near-continuous ventricular pacing may face earlier battery depletion than someone paced intermittently. Clinicians should explain whether the device can be retrieved, whether a new device would be implanted alongside the old one, and how future valve procedures might interact with the pacing system.

Planning Around Valve Surgery And Intervention

The timing of implantation matters when tricuspid valve intervention is planned. Implanting a transvenous lead before surgery may create avoidable difficulties, while placing a leadless device after valve replacement may be complicated by altered right ventricular geometry, anticoagulation, or postoperative haemodynamic instability. A joint plan from electrophysiology, structural heart, imaging, cardiac surgery, and anaesthesia teams is preferable.

In patients with a tricuspid prosthesis, imaging should confirm that the delivery system can be advanced safely and that the device will not obstruct prosthetic function. Mechanical valves require particular caution because of the risk associated with crossing the valve and the implications of lifelong anticoagulation. A leadless device positioned in the right ventricle does not eliminate all procedural concerns, but it avoids chronic interaction between a pacing lead and the tricuspid apparatus.

Australian referral patterns can make this coordination challenging. A patient living in regional Queensland or Western Australia may need travel to Brisbane, Perth, Melbourne, or Sydney for advanced imaging and implantation. Early referral is valuable because it allows device procurement, anticoagulation planning, and postoperative care to be organised before the patient becomes unstable.

Procedural And Periprocedural Considerations

Femoral venous access, fluoroscopy, intracardiac echocardiography, and careful device positioning are central to implantation. Pre-procedure imaging can identify inferior vena cava obstruction, unusual venous anatomy, or a markedly enlarged right heart. In patients with pulmonary hypertension or advanced right-sided failure, anaesthetic planning deserves particular attention because sedation, positive-pressure ventilation, and fluid shifts can destabilise circulation.

Anticoagulation management must be individualised. A patient with atrial fibrillation, a bioprosthetic valve, or another indication for anticoagulation may need a carefully timed interruption or continuation strategy. Mechanical valve patients require specialist planning, and bridging should not be applied automatically. Bleeding risk at the femoral access site must be balanced against thromboembolic risk.

The procedure should include a plan for managing perforation, tamponade, device embolisation, and vascular complications. High-volume centres may have greater experience with complex anatomy, but outcomes depend on operator expertise, imaging support, emergency surgical access, and institutional protocols. Consent should cover the possibility of conversion to another pacing strategy if deployment is unsuccessful.

Monitoring Outcomes And Long-Term Care

After implantation, device interrogation should confirm sensing, capture threshold, impedance where applicable, and pacing percentage. Echocardiography provides a baseline for subsequent assessment of right ventricular function and tricuspid regurgitation. A leadless system may reduce the chance of lead-related valve deterioration, but it does not treat the underlying valve disease or reverse established right-sided remodelling.

Follow-up should address symptoms, battery estimates, pacing dependence, arrhythmia burden, and changes in valve status. Patients should receive clear instructions about femoral wound care, infection symptoms, syncope, palpitations, and worsening breathlessness. Remote monitoring availability varies between devices and services, so arrangements should be practical for people who live far from the implanting centre.

In Australia, follow-up may involve a metropolitan electrophysiology clinic, a local cardiologist, and a regional hospital. Communication through shared electronic records and structured device reports can reduce gaps in care, especially when patients move between public and private services. Clinicians should also record the device model and implant details clearly for future procedures, magnetic resonance imaging decisions, and emergency presentations.

Weighing Benefits Against Limitations

The principal benefit is anatomical: no lead traverses the tricuspid valve. This can be persuasive for patients with severe regurgitation, prior valve surgery, or a high likelihood of future tricuspid intervention. The absence of a generator pocket may reduce infection and wound complications, and the cosmetic result may be attractive to some patients.

The limitations are equally important. Most leadless systems provide less flexibility than a conventional dual-chamber or cardiac resynchronisation system. Retrieval may become more difficult over time because of endothelialisation, and repeated implants may occupy right ventricular space. Perforation risk, vascular complications, battery depletion, and the need for specialised extraction or replacement planning remain relevant.

Access and cost also influence real-world decisions. Australian hospitals assess devices through local procurement processes, TGA approval, clinical indications, and funding arrangements across public and private care. A device available in a major Sydney or Melbourne centre may not be immediately accessible in a smaller hospital. These practical factors should be discussed transparently without allowing them to replace clinical reasoning.

A leadless pacemaker can be an important solution when tricuspid valve preservation is a priority and ventricular pacing is sufficient. The best results come from matching the device to the rhythm disorder, valve anatomy, procedural setting, and anticipated future care. Electrophysiology teams should document the rationale, alternatives, and follow-up plan in a way that remains useful to every clinician involved.

Clinicians and researchers can contribute to better practice by reporting valve outcomes, right ventricular performance, complications, device longevity, and patient-reported effects in people with tricuspid disease. Reviewing current evidence and submitting carefully documented clinical research through the Journal of Arrhythmia can help refine selection criteria and support safer pacing pathways across Australia.